ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 964

Atherogenic Potency of Plasma from Persons with Autoimmune Rheumatic Disorders: Comparative Effects on Cholesterol Flux in Human Macrophages

Andrew Maidhof1, Allison B. Reiss1,2, Lora J. Kasselman2, Elise Belilos1, Kristina Belostocki1, Gary Rosenblum1, Lois Bonnetti1, Melissa Fazzari2, Joshua DeLeon1 and Steven E. Carsons1,2, 1NYU Winthrop University Hospital, Department of Medicine, Mineola, NY, 2NYU Winthrop University Hospital, Winthrop Research Institute, Mineola, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: Atherosclerosis, Cardiovascular disease, cholesterol and rheumatic disease

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis Poster II: Mesenchymal Cells Do React - But How?

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Although the risk of atherosclerotic cardiovascular disease and abnormalities in cholesterol transport have been demonstrated in rheumatoid arthritis (RA), lupus (SLE) and, to a lesser extent, in psoriatic arthritis (PsA), the degree of cholesterol transport abnormalities is not known. This study examines the effect of RA, PsA, and SLE versus healthy control (HC) plasma on cholesterol transport genes. Particular genes affect atherosclerotic processes by modulating cholesterol influx, catabolism, and efflux. Dysfunctional cholesterol handling underlies mechanisms that promote atherosclerosis.

Methods:

THP-1 human macrophages (106/ml) were incubated (18h-24h, RPMI1640 media) in the presence of 10% plasma from patients diagnosed as follows: 8 RA females; 12 SLE (9 female, 3 male), 22 PsA (7 female, 15 male); 21 HC (21 female). Cholesterol transport mRNA was quantified by real-time RT-PCR using specific primers for each gene. Statistical analysis was performed using Graphpad Prism. All data were analyzed by one-way analysis of variance, and pairwise multiple comparisons were made between control and treatment conditions using Bonferroni correction. RA patients fulfilled the 2010 revised criteria of the American College of Rheumatology for classification of RA. SLE patients fulfilled the Systemic Lupus International Collaborating Clinics Classification Criteria of 2012. PsA patients fulfilled the Classification Criteria for Psoriatic Arthritis of 2006. Patients with previous documentation of a diagnosis of a connective tissue disorder other than RA, PsA or SLE were excluded.

Results:

SLE: 10% SLE plasma increased cholesterol influx gene expression. CD36 mRNA increased by 220±56% (P<0.001), LOX-1 by 202±22% (P<0.001), and SR-A1 increased to 122.0±45.0% versus HC plasma (set at 100%). Efflux genes were suppressed. ABCA1 mRNA decreased to 77.0±47.0%, ABCG1 to 89.0±33.0%, and 27-hydroxylase (27-OH) mRNA to 20.0±48.0% versus HC.

RA: 10% RA plasma increased CD36 by 157.4±111.0%, SR-A1 to 124±19.0%, and LOX-1 to 102.0±53.0% versus HC. Mean ABCA1 mRNA decreased to 65.7±28.4 (P<0.001), ABCG1 to 65.0±47.0% (P<0.05), and 27-OH to 32.5±14.2% (P<0.01) in RA treated plasma versus HC plasma.

PsA: 10 % PsA plasma didn’t alter message level of influx nor efflux genes. However, levels of SR-A1 decreased to 80.0±30.0%.

Conclusion:

Consistent with clinic evidence, cholesterol transport abnormalities are most deranged in SLE. RA and SLE plasma induced a consistent pro-atherogenic profile of cholesterol flux genes. PsA plasma was less atherogenic, reflecting their lesser disease-related cardiovascular risk. These results identify cholesterol transport genes as a potential new therapeutic target for atherosclerosis prevention in the setting of autoimmunity.


Disclosure: A. Maidhof, None; A. B. Reiss, None; L. J. Kasselman, None; E. Belilos, None; K. Belostocki, None; G. Rosenblum, None; L. Bonnetti, None; M. Fazzari, None; J. DeLeon, None; S. E. Carsons, None.

To cite this abstract in AMA style:

Maidhof A, Reiss AB, Kasselman LJ, Belilos E, Belostocki K, Rosenblum G, Bonnetti L, Fazzari M, DeLeon J, Carsons SE. Atherogenic Potency of Plasma from Persons with Autoimmune Rheumatic Disorders: Comparative Effects on Cholesterol Flux in Human Macrophages [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/atherogenic-potency-of-plasma-from-persons-with-autoimmune-rheumatic-disorders-comparative-effects-on-cholesterol-flux-in-human-macrophages/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/atherogenic-potency-of-plasma-from-persons-with-autoimmune-rheumatic-disorders-comparative-effects-on-cholesterol-flux-in-human-macrophages/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology